Showing 4321-4330 of 8850 results for "".
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expressio
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Study Highlights Potential Minoxidil Shortagehttps://practicaldermatology.com/news/study-highlights-potential-minoxidil-shortage/2462107/Minoxidil may be in short supply at some pharmacies, potentially jeopardizing patients’ efforts to treat hair loss, according to new research in the
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- New Insights on the Genetic Link Between Skin Tone and Ancestral Originhttps://practicaldermatology.com/news/new-insights-on-the-genetic-link-between-skin-tone-and-ancestral-origin/2462096/The link between skin pigmentation and ethnicity is more complicated than previously believed, according to new research published in the journal eLife. The team has confirmed that genes associated with East Asian and Native American anc
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Tralokinumab Controls AD Over the Long Termhttps://practicaldermatology.com/news/adtralza-tralokinumab-controls-ad-over-the-long-term/2462069/Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and V
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.